PEMBROLIZUMAB + Porustobart for spinocerebellar degenerations

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Sep 2026: Trial registered, NCT07808151

The trials

NCT07808151: Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

State
Under way
Phase
Phase 2
People
100 planned
Started
30 Nov 2026
Primary completion
30 Sep 2029
Arms
Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab
Results
None posted
  1. 8 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.